Research Paper Volume 11, Issue 22 pp 10644—10663

Figure 1. MYSM1 is downregulated in castration-resistant prostate cancer and inversely correlated with progression of prostate cancer. (A) Pan-cancer analyses for mean expression levels of MYSM1 in different types of cancers. (B) MYSM1 mRNA levels in prostate cancers (T = tumor, N = normal, PRAD = prostate adenocarcinoma). Data (A–B) were acquired from TCGA database and analyzed via GEPIA bioinformatics. (C) Representative IHC staining images of MYSM1 in benign prostatic hyperplasia (BPH) and prostate cancer (PCa) tissues. Scale bars are 20 μm. (D–E) MYSM1 expression levels based on Grasso Prostate dataset from Oncomine database. (F–I) MYSM1 is differentially expressed in prostate cancer patients and data acquired from Taylor Prostate 3 cohort are analyzed based on Gleason grade (F), Gleason score (G), N stage (H) and recurrence status (I) via Oncomine database. Data are shown as mean ± SD. n.s = no significance, * P < 0.05 and ** P < 0.01 (Student’s t-test). (J–K) Correlation of MYSM1 with overall survival (J) and recurrence-free survival (K) in prostate cancer patients (n = 140). Data were acquired from Taylor Prostate 3 cohort via Oncomine database. Log-rank test was applied to determine the significance levels.